All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

AMGNAmgen
2Calm
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer
Running, no new patientsPhase 3145 patientsMain results: Mar 10, 2026
CABACabaletta Bio
0Calm
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Signing up patientsPhase 1/224 patientsMain results: Sep 2029
PTGXProtagonist Therapeutics, Inc.
1Calm
A Study of Rusfertide in Adults With Polycythemia Vera (PV)
Running, no new patientsPhase 3293 patientsMain results: Feb 21, 2025
NVSNovartis Pharmaceuticals
5Calm
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Running, no new patientsPhase 1/2344 patientsMain results: Jan 25, 2027
AZNAstraZeneca
0Calm
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Signing up patientsPhase 3150 patientsMain results: Feb 28, 2029
ABBVAbbVie
1Calm
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Signing up patientsPhase 2/3680 patientsMain results: Mar 2041
NUVBNuvation Bio Inc.
0Calm
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Signing up patientsPhase 3365 patientsMain results: Dec 1, 2028
ABBVAbbVie
1Calm
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Running, no new patientsPhase 2/3167 patientsMain results: Oct 2031
DCTHDelcath Systems Inc.
0Calm
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Signing up patientsPhase 290 patientsMain results: May 2029
GSKGlaxoSmithKline
0Calm
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Signing up patientsPhase 1/2346 patientsMain results: Jan 9, 2029
PFEPfizer
0Calm
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Signing up patientsPhase 3400 patientsMain results: Jul 22, 2027
GSKGlaxoSmithKline
0Calm
Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
Not started yetPhase 3378 patientsMain results: Nov 5, 2030
NVSNovartis Pharmaceuticals
5Calm
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Running, no new patientsPhase 2168 patientsMain results: Mar 15, 2032
ONCBeOne Medicines
2Calm
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Signing up patientsPhase 230 patientsMain results: Dec 31, 2031
AZNAstraZeneca
0Calm
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Signing up patientsPhase 3600 patientsMain results: Sep 29, 2028
AZNAstraZeneca
0Calm
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Signing up patientsPhase 3840 patientsMain results: Apr 27, 2029
SMMTSummit Therapeutics
0Calm
A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer
Not started yetPhase 2100 patientsMain results: Apr 12, 2029
BNTXBioNTech SE
0Calm
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
Signing up patientsPhase 3480 patientsMain results: Mar 2028
AZNAstraZeneca
0Calm
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Signing up patientsPhase 32,130 patientsMain results: Aug 16, 2029
BNTXBioNTech SE
0Calm
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Signing up patientsPhase 3736 patientsMain results: Feb 2031
PFEPfizer
0Calm
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
Running, no new patientsPhase 31,035 patientsMain results: Jan 2, 2029
AZNAstraZeneca
0Calm
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Running, no new patientsPhase 3760 patientsMain results: Jan 2, 2029
MRKMerck Sharp & Dohme LLC
5Calm
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Signing up patientsPhase 290 patientsMain results: Mar 12, 2032
AZNAstraZeneca
0Calm
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
Running, no new patientsPhase 3760 patientsMain results: Feb 23, 2026
AZNAstraZeneca
0Calm
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Signing up patientsPhase 1/283 patientsMain results: Oct 11, 2028